Besides eradicating tumour cells with deficiencies for homologous recombination, PARP inhibitors can induce the activation of CAFs within the TME via NF-κB/CCL5 pathway. CCL5 blockade blunts the reprogramming of CAFs conditioned by PARP inhibitors and potentiates PARP inhibitors.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activites described below. To learn more about how these trackers help us